The Prostate Health Education Network: Prostate Health Education and Awareness

Clinical Trials

A Study of Enzalutamide and Mifepristone in Treating Patients With Prostate Cancer Number: NCT02012296 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Chicago\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s)	Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer Number: NCT02452008 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|Eli Lilly and Company Sponsor Trial Information Trial Location(s) and Contact(s)
Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer Number: NCT02516670 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s)	Enzalutamide With and Without Ribociclib for mCRPC patients who have not received chemotherapy Number: NCT02555189 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Sidney Kimmel Cancer Center at Thomas Jefferson University\|Novartis\|Prostate Cancer Clinical Trials Consortium\|Thomas Jefferson University Sponsor Trial Information Trial Location(s) and Contact(s)
Use of Ligand-Inducible Autologous T Cells Engineered to Target PSCA on Tumor Cells in Selected Advanced Solid Tumors Number: NCT02744287 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Bellicum Pharmaceuticals Sponsor Trial Information Trial Location(s) and Contact(s)	Trial of CRLX101, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer Number: NCT02769962 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1/2 Sponsor(s): National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s)
Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With mCRPC Number: NCT02807805 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Chong-xian Pan\|National Cancer Institute (NCI)\|University of California, Davis Sponsor Trial Information Trial Location(s) and Contact(s)	Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC) Number: NCT02903160 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Icahn School of Medicine at Mount Sinai\|Sanofi\|Bayer Sponsor Trial Information Trial Location(s) and Contact(s)
PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer Number: NCT02933255 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s)	Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer Number: NCT02935205 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of California, Davis\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s)
A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency Number: NCT02975934 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Clovis Oncology, Inc.\|Foundation Medicine Sponsor Trial Information Trial Location(s) and Contact(s)	Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies Number: NCT02985021 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Seattle Institute for Biomedical and Clinical Research\|Prostate Cancer Foundation\|VA Puget Sound Health Care System Sponsor Trial Information Trial Location(s) and Contact(s)
Study of Nivolumab Plus Ipilimumab, Ipilimumab or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer Number: NCT02985957 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Bristol-Myers Squibb Sponsor Trial Information Trial Location(s) and Contact(s)	Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With mCRPC With DNA Repair Defects Number: NCT03012321 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Northwestern University\|AstraZeneca\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s)
Clinical Study of change in brain structure or activity in men treated with androgen receptor therapies such as abiraterone acetate and enzalutamide Number: NCT03016741 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 4 Sponsor(s): Northwestern University Sponsor Trial Information Trial Location(s) and Contact(s)	Apalutamide and Abiraterone Acetate in African American and Caucasian Men With mCRPC Number: NCT03098836 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Daniel George, MD\|Janssen Scientific Affairs, LLC\|Duke University Sponsor Trial Information Trial Location(s) and Contact(s)
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Number: NCT03170960 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Exelixis Sponsor Trial Information Trial Location(s) and Contact(s)	Using Imaging for Detection of mCRPC Number: NCT03173924 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s)
Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies Number: NCT03217747 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1/2 Sponsor(s): M.D. Anderson Cancer Center\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s)	Pembrolizumab in mCRPC With or Without DNA Damage Repair Defects Number: NCT03248570 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of California, San Francisco Sponsor Trial Information Trial Location(s) and Contact(s)
Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer Number: NCT03298087 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): VA Office of Research and Development Sponsor Trial Information Trial Location(s) and Contact(s)	Radium-223 and Radiotherapy in Hormone-Naïve Men With Oligometastatic Prostate Cancer to Bone Number: NCT03304418 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Utah\|Bayer Sponsor Trial Information Trial Location(s) and Contact(s)
Olaparib and Radium Ra 223 Dichloride in Treating Men With Metastatic Castration-Resistant Prostate Cancer That Has Spread to the Bone Number: NCT03317392 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1/2 Sponsor(s): National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s)	An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer Number: NCT03338790 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Bristol-Myers Squibb\|Clovis Oncology, Inc.\|Astellas Pharma Inc Sponsor Trial Information Trial Location(s) and Contact(s)
Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer Number: NCT03344211 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Southern California\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s)	Study of Apalutamide and Abiraterone Acetate in Castration-Resistant Bone Metastatic Prostate Cancer Patients Number: NCT03360721 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): M.D. Anderson Cancer Center\|Janssen Scientific Affairs, LLC Sponsor Trial Information Trial Location(s) and Contact(s)
Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer Number: NCT03361735 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): City of Hope Medical Center Sponsor Trial Information Trial Location(s) and Contact(s)	Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC With Deoxyribonucleic Acid (DNA) Damage Repair Deficiencies (DDR) Number: NCT03395197 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Pfizer Sponsor Trial Information Trial Location(s) and Contact(s)
Pembrolizumab and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer Number: NCT03406858 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Barbara Ann Karmanos Cancer Institute\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s)	Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With mCRPC Number: NCT03414034 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Trovagene, Inc. Sponsor Trial Information Trial Location(s) and Contact(s)
A Study of Niraparib Combination Therapies for the Treatment of mCRPC Number: NCT03431350 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Janssen Research & Development, LLC Sponsor Trial Information Trial Location(s) and Contact(s)	Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With mCRPC Number: NCT03437941 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1/2 Sponsor(s): Corcept Therapeutics Sponsor Trial Information Trial Location(s) and Contact(s)
Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency Number: NCT03442556 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Washington\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s)	Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer Number: NCT03456843 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Rutgers, The State University of New Jersey\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s)
177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer Number: NCT03490838 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Advanced Accelerator Applications Sponsor Trial Information Trial Location(s) and Contact(s)	Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, ALT-803 and Epacadostat (QuEST1) Number: NCT03493945 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s)
Testosterone Enanthate and Olaparib in Treating Participants With Castration-Resistant Prostate Cancer Number: NCT03516812 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Washington\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s)	M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Number: NCT03517969 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s)
Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment Number: NCT03531827 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s)	177Lu−J591 and 177Lu−PSMA−617 Combination for mCRPC Number: NCT03545165 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1/2 Sponsor(s): Weill Medical College of Cornell University Sponsor Trial Information Trial Location(s) and Contact(s)
COMbination of Bipolar Androgen Therapy and Nivolumab Number: NCT03554317 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|Bristol-Myers Squibb Sponsor Trial Information Trial Location(s) and Contact(s)	Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer Number: NCT03565835 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Montefiore Medical Center Sponsor Trial Information Trial Location(s) and Contact(s)
Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based Biomarkers Number: NCT03585114 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Emerson Lim\|Columbia University Sponsor Trial Information Trial Location(s) and Contact(s)	This Study is to Evaluate OBI-3424 Safe and Effective Treatment Dose in Subjects With Hepatocellular Carcinoma or Castrate Resistant Prostate Cancer Number: NCT03592264 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): OBI Pharma, Inc Sponsor Trial Information Trial Location(s) and Contact(s)
Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency Number: NCT03712930 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): BeiGene Sponsor Trial Information Trial Location(s) and Contact(s)	IMMU-132 in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy Number: NCT03725761 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Wisconsin, Madison\|National Cancer Institute (NCI)\|Immunomedics, Inc. Sponsor Trial Information Trial Location(s) and Contact(s)
Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer Number: NCT03751436 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Roswell Park Cancer Institute\|National Cancer Institute (NCI)\|AbbVie Sponsor Trial Information Trial Location(s) and Contact(s)	To Evaluate Safety and Tolerability of VERU-111 in Men With Advanced Metastatic Castration Resistant Prostate Cancer Number: NCT03752099 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Veru Inc. Sponsor Trial Information Trial Location(s) and Contact(s)
A Study of Avelumab Plus ADT in African American Subjects with mCRPC Number: NCT03770455 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: 2 Sponsor(s): EMD Serono\|Tulane University Sponsor Trial Information Trial Location(s) and Contact(s)	Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 160 in Subjects with MCRPC Number: NCT03792841 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Amgen Sponsor Trial Information Trial Location(s) and Contact(s)
Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer Number: NCT03800784 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2/3 Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Sponsor Trial Information Trial Location(s) and Contact(s)	18F-DCFPyL Positron Emission Tomography (PET)/Computed Tomography (CT) in Men With Prostate Cancer Number: NCT03824275 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2/3 Sponsor(s): Columbia University Sponsor Trial Information Trial Location(s) and Contact(s)
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641) Number: NCT03834493 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Merck Sharp & Dohme Corp. Sponsor Trial Information Trial Location(s) and Contact(s)	Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921) Number: NCT03834506 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Merck Sharp & Dohme Corp. Sponsor Trial Information Trial Location(s) and Contact(s)
Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010) Number: NCT03834519 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Merck Sharp & Dohme Corp. Sponsor Trial Information Trial Location(s) and Contact(s)	Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors Number: NCT03866382 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s)
The Safety and Tolerability of Proxalutamide (GT0918) in Subjects With Metastatic Castrate Resistant Prostate Cancer Number: NCT03899467 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Suzhou Kintor Pharmaceutical Inc, Sponsor Trial Information Trial Location(s) and Contact(s)	Phase 2 of Carbo, Taxel and Abi in Metastatic Castration Prostate Cancer Number: NCT03934840 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Masonic Cancer Center, University of Minnesota Sponsor Trial Information Trial Location(s) and Contact(s)
Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer Number: NCT03972657 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Regeneron Pharmaceuticals Sponsor Trial Information Trial Location(s) and Contact(s)	Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer Number: NCT03999515 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Washington\|National Cancer Institute (NCI)\|Janssen Research & Development, LLC Sponsor Trial Information Trial Location(s) and Contact(s)
ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer Number: NCT04028388 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Modra Pharmaceuticals Sponsor Trial Information Trial Location(s) and Contact(s)	sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Number: NCT04033432 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Northwestern University\|Vasgene Therapeutics, Inc\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s)
BRcA Deficient Prostate Cancer Treated With Carboplatin or Docetaxel Number: NCT04038502 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): VA Office of Research and Development Sponsor Trial Information Trial Location(s) and Contact(s)	Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC Number: NCT04060394 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Laekna Limited Sponsor Trial Information Trial Location(s) and Contact(s)
A Phase 2 Trial for Men With Metastatic Prostatic Adenocarcinoma Number: NCT04090775 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Rampart Health, L.L.C. Sponsor Trial Information Trial Location(s) and Contact(s)	A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer Number: NCT04100018 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Bristol-Myers Squibb Sponsor Trial Information Trial Location(s) and Contact(s)
A Study of Checkpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation Number: NCT04104893 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): VA Office of Research and Development\|Merck Sharp & Dohme Corp. Sponsor Trial Information Trial Location(s) and Contact(s)	Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer. Number: NCT04116775 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Julie Graff, MD\|Merck Sharp & Dohme Corp.\|Prostate Cancer Foundation\|Johns Hopkins University\|Oregon Health and Science University\|Portland VA Medical Center Sponsor Trial Information Trial Location(s) and Contact(s)
Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC) Number: NCT04157088 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Bayer Sponsor Trial Information Trial Location(s) and Contact(s)	18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Abiraterone Acetate Number: NCT04158245 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Tulane University\|Blue Earth Diagnostics Sponsor Trial Information Trial Location(s) and Contact(s)
Addition of Opaganib to Androgen Antagonists in Patients With mCRPC Number: NCT04207255 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Medical University of South Carolina\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s)	Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer Number: NCT04221542 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): http://www.amgentrials.com/amgen/studysearch.aspx?SearchStr=amg+160 Sponsor Trial Information Trial Location(s) and Contact(s)
A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer Number: NCT04253262 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1/2 Sponsor(s): Brown University\|Rhode Island Hospital\|The Miriam Hospital\|Bayer\|Clovis Oncology, Inc. Sponsor Trial Information Trial Location(s) and Contact(s)	Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer Number: NCT04381832 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1/2 Sponsor(s): Arcus Biosciences, Inc. Sponsor Trial Information Trial Location(s) and Contact(s)

Total: 74 Clinical Trials

PHEN,Inc. © 2020 All rights reserved